DDX11L8: A Potential Drug Target and Biomarker for ALS (G100302090)

Target Name: DDX11L8

NCBI ID: G100302090

DDX11L8

Other Name(s): DEAD/H-box helicase 11 like 8 (pseudogene)

DDX11L8: A Potential Drug Target and Biomarker for ALS

Ammonium-rich sphingomyelin (AMyloid) is a major protein that accumulates in the brains of individuals with Alzheimer's disease (AD). It is estimated that over 50 million people worldwide have AD, and the number of cases is expected to reach 80 million by 2030 due to the aging population. The disease is characterized by progressive memory loss, stiffness, and difficulty swallowing, which ultimately lead to decreased quality of life and independence.

One of the main causes of AD is the formation of aggregated AMyloid plaques, which cause inflammation and nerve cell damage. While there are currently no cure for AD, treatments such as medications to reduce inflammation and remove the plaque have been shown to slow down the progression of the disease and improve quality of life.

DDX11L8 is a protein that is expressed in the brain and has been shown to interact with the amyloid protein. It is a 11-kDa protein that is involved in the formation of AMyloid plaques and has been shown to contribute to the development of neurodegenerative diseases.

Potential Drug Target

DDX11L8 has been identified as a potential drug target for the treatment of neurodegenerative diseases, including AD. By targeting the DDX11L8 protein, researchers hope to reduce the formation of AMyloid plaques and slow down the progression of neurodegenerative diseases.

One way to target DDX11L8 is through the use of small molecules, which can interact with the protein and disrupt its activity. Researchers have synthesized several small molecules that have been shown to interact with DDX11L8 and reduce the formation of AMyloid plaques.

Biomarker

DDX11L8 has also been identified as a potential biomarker for the early detection of neurodegenerative diseases, including AD. The protein can be used as a diagnostic marker to determine the presence of AMyloid plaques and to monitor the progression of neurodegenerative diseases.

While the use ofDDX11L8 as a drug target or biomarker is still in its early stages, it holds great promise for the treatment of neurodegenerative diseases. Further research is needed to fully understand the potential of DDX11L8 as a drug target and biomarker for neurodegenerative diseases.

Conclusion

DDX11L8 is a protein that has been shown to interact with the amyloid protein, which is a major cause of neurodegenerative diseases. Further research has shown that DDX11L8 can be used as a potential drug target and biomarker for the treatment of these diseases.

While the use of DDX11L8 is still in its early stages, it holds great promise for the future treatment of neurodegenerative diseases. Further research is needed to fully understand the potential of DDX11L8 as a drug target and biomarker for these diseases.

Protein Name: DEAD/H-box Helicase 11 Like 8 (pseudogene)

The "DDX11L8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DDX11L8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets